Limits...
Chronic hepatitis B and C co-infection increased all-cause mortality in HAART-naive HIV patients in Northern Thailand.

Tsuchiya N, Pathipvanich P, Rojanawiwat A, Wichukchinda N, Koga I, Koga M, Auwanit W, Kilgore PE, Ariyoshi K, Sawanpanyalert P - Epidemiol. Infect. (2012)

Bottom Line: Eight (9.6%) HBV co-infected patients did not have anti-HBV core antibody (anti-HBcAb).Interestingly, HBV co-infection without anti-HBc Ab was strongly associated with death (aHR 6.34, 95% CI 3.99–10.3).The influence of hepatitis co-infection on the natural history of HAART-naive HIV patients requires greater attention.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Medicine, Institute of Tropical Medicine NEKKEN, Nagasaki University, Japan.

ABSTRACT
A total of 755 highly active antiretroviral therapy (HAART)-naive HIV-infected patients were enrolled at a government hospital in Thailand from 1 June 2000 to 15 October 2002. Census dateo f survival was on 31 October 2004 or the date of HAART initiation. Of 700 (92.6%) patients with complete data, the prevalence of hepatitis B virus (HBV) surface antigen and anti-hepatitis C virus (HCV) antibody positivity was 11.9% and 3.3%, respectively. Eight (9.6%) HBV co-infected patients did not have anti-HBV core antibody (anti-HBcAb). During 1166.7 person-years of observation (pyo), 258 (36.9%) patients died [22.1/100 pyo, 95% confidence interval (CI) 16.7–27.8]. HBV and probably HCV co-infection was associated with a higher mortality with adjusted hazard ratios (aHRs) of 1.81 (95% CI 1.30–2.53) and 1.90 (95% CI0.98–3.69), respectively. Interestingly, HBV co-infection without anti-HBc Ab was strongly associated with death (aHR 6.34, 95% CI 3.99–10.3). The influence of hepatitis co-infection on the natural history of HAART-naive HIV patients requires greater attention.

Show MeSH

Related in: MedlinePlus

Kaplan–Meier survival probability estimate showing that HBV co-infected individuals without anti-HBcAb had the poorest survival compared to HIV mono-infected or HBV co-infected patients with anti-HBcAb.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3757365&req=5

fig02: Kaplan–Meier survival probability estimate showing that HBV co-infected individuals without anti-HBcAb had the poorest survival compared to HIV mono-infected or HBV co-infected patients with anti-HBcAb.

Mentions: Survival estimates focused on HBV serology interestingly showed that HBV co-infected individuals without anti-HBcAb had the poorest survival compared to HIV mono-infected or HBV co-infected patients with anti-HBcAb (P < 0·0001 by log-rank test, Fig. 2). In multivariate analysis (Table 3b), in addition to symptomatic AIDS and low CD4 cell count, HBV co-infection without anti-HbcAb was a strong risk factor for death (adjusted HR 6·34, 95% CI 3·99–10·3).Fig. 2.


Chronic hepatitis B and C co-infection increased all-cause mortality in HAART-naive HIV patients in Northern Thailand.

Tsuchiya N, Pathipvanich P, Rojanawiwat A, Wichukchinda N, Koga I, Koga M, Auwanit W, Kilgore PE, Ariyoshi K, Sawanpanyalert P - Epidemiol. Infect. (2012)

Kaplan–Meier survival probability estimate showing that HBV co-infected individuals without anti-HBcAb had the poorest survival compared to HIV mono-infected or HBV co-infected patients with anti-HBcAb.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3757365&req=5

fig02: Kaplan–Meier survival probability estimate showing that HBV co-infected individuals without anti-HBcAb had the poorest survival compared to HIV mono-infected or HBV co-infected patients with anti-HBcAb.
Mentions: Survival estimates focused on HBV serology interestingly showed that HBV co-infected individuals without anti-HBcAb had the poorest survival compared to HIV mono-infected or HBV co-infected patients with anti-HBcAb (P < 0·0001 by log-rank test, Fig. 2). In multivariate analysis (Table 3b), in addition to symptomatic AIDS and low CD4 cell count, HBV co-infection without anti-HbcAb was a strong risk factor for death (adjusted HR 6·34, 95% CI 3·99–10·3).Fig. 2.

Bottom Line: Eight (9.6%) HBV co-infected patients did not have anti-HBV core antibody (anti-HBcAb).Interestingly, HBV co-infection without anti-HBc Ab was strongly associated with death (aHR 6.34, 95% CI 3.99–10.3).The influence of hepatitis co-infection on the natural history of HAART-naive HIV patients requires greater attention.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Medicine, Institute of Tropical Medicine NEKKEN, Nagasaki University, Japan.

ABSTRACT
A total of 755 highly active antiretroviral therapy (HAART)-naive HIV-infected patients were enrolled at a government hospital in Thailand from 1 June 2000 to 15 October 2002. Census dateo f survival was on 31 October 2004 or the date of HAART initiation. Of 700 (92.6%) patients with complete data, the prevalence of hepatitis B virus (HBV) surface antigen and anti-hepatitis C virus (HCV) antibody positivity was 11.9% and 3.3%, respectively. Eight (9.6%) HBV co-infected patients did not have anti-HBV core antibody (anti-HBcAb). During 1166.7 person-years of observation (pyo), 258 (36.9%) patients died [22.1/100 pyo, 95% confidence interval (CI) 16.7–27.8]. HBV and probably HCV co-infection was associated with a higher mortality with adjusted hazard ratios (aHRs) of 1.81 (95% CI 1.30–2.53) and 1.90 (95% CI0.98–3.69), respectively. Interestingly, HBV co-infection without anti-HBc Ab was strongly associated with death (aHR 6.34, 95% CI 3.99–10.3). The influence of hepatitis co-infection on the natural history of HAART-naive HIV patients requires greater attention.

Show MeSH
Related in: MedlinePlus